Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.

Also called NCT01043380

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 245 participants (enrolled count) (from the registry)
Sponsor
Kumamoto University (from the registry)
Registry
  • NCT NCT01043380
Other papers using this trial's data
  • Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial Journal of the American College of Cardiology, 2015-08-04 DOI, PubMed 26227186
  • Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial International journal of cardiology, 2018-10-01 DOI, PubMed 29925472
  • Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial Atherosclerosis, 2016-08 DOI, PubMed 27318866

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01043380. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2014-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound
Acronym
PRECISE-IVUS
Condition
Hypercholesterolemia
Intervention (Drug)
Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]
Intervention (Drug)
Lipitor (Atorvastatin) monotherapy
Lead sponsor
Kumamoto University (class: other)

Record details

Record id
cardio:ct-nct01043380
Content hash
3565e0e30126a9217e07563cdcbfd71300e7ec47131c7c08ec2bc8da98745b71